Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03746535 · ClinicalTrials.gov registry record · Early Phase 1
Cardiovascular Disease Risk in Women With Endometriosis
A Early Phase 1 study of Endometriosis, sponsored by Yale University.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT03746535: Recruiting Early Phase 1 study of Endometriosis, sponsored by Yale University.
NCT03746535 is a Early Phase 1 study of Endometriosis that is actively recruiting participants, run by Yale University. The registered enrollment target is 40 participants, below the 263-participant average among 48 other Endometriosis trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03746535, a Early Phase 1 study of Endometriosis, is actively recruiting participants, sponsored by Yale University.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
To test the hypothesis that estrogen suppression impairs endothelial dysfunction in endometriosis.
Primary Outcome
Blood flow velocity will be measured using the Sonoscope S2 ultrasound imaging system.
Conditions Studied
Interventions
- DRUG Elagolix
Study Locations (1)
Connecticut
- Yale School of Medicine - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2022-07-01 |
| Est. Completion | 2026-12-31 |
| Phase | Early Phase 1 |
What NCT03746535 shows while recruiting
NCT03746535 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 263-participant average among 48 other Endometriosis trials with a reported enrollment target (85% lower).
The record links to 1 condition, with Endometriosis appearing as the primary indexed condition, and to 1 intervention - of which Elagolix is the first listed.
NCT03746535 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT03746535 about?
NCT03746535 is a clinical study titled "Cardiovascular Disease Risk in Women With Endometriosis". To test the hypothesis that estrogen suppression impairs endothelial dysfunction in endometriosis.
What is the current status of trial NCT03746535?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 40 participants. The study started on 2022-07-01. Estimated completion is 2026-12-31.
What conditions does trial NCT03746535 study?
This clinical trial studies the following conditions: Endometriosis.
What interventions are being tested in trial NCT03746535?
The interventions under investigation include: Elagolix (DRUG).
Who is sponsoring clinical trial NCT03746535?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03746535 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Endometriosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03746535's enrollment target sits among peer trials
40 39th of 48 higher than 10 of 48 other Endometriosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Endometriosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Endometriosis and Microvascular Dysfunction: Role of Inflammation
RECRUITING · Early Phase 1
-
Thromboxane Function in Women With Endometriosis
RECRUITING · Phase 4
-
Interdisciplinary Group Care for the Treatment of Endometriosis-associated Pain
RECRUITING · NA
-
The Impact of Yoga on Endometriosis-Related Pain
RECRUITING · NA
-
Physical Therapy After Endometriosis Excision
RECRUITING · NA
-
Evaluation of Endometriosis With 18F-fluorofuranylnorprogesterone PET / MRI
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI